1-8 of 8
George Muller
Close
Sort by
Journal Articles

Direct Inhibitory Effects of Lenalidomide on the Proliferation and VEGF Production of Non-Hodgkin Lymphoma Cells Are Associated with Increased SPARC Expression

Ling-Hua Zhang, Peter H Schafer, George Muller, David Stirling, Blake Bartlett
Journal: Blood
Blood (2008) 112 (11): 2612.
https://doi.org/10.1182/blood.V112.11.2612.2612
Published: 2008
Journal Articles

Lenalidomide Enhancement of NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Is Mediated by Granzyme B and FasL and Is Associated with Modification of SHIP-1, PLC-g2 and pERK and Enhanced Chemokine Production.

Lei Wu, MD, Mary Adams, MS, Peter Schafer, PhD, George Muller, PhD, David Stirling, PhD, Blake J. Bartlett, PhD
Journal: Blood
Blood (2007) 110 (11): 4885.
https://doi.org/10.1182/blood.V110.11.4885.4885
Published: 2007
Journal Articles

Lenalidomide Displays Direct Anti-Non-Hodgkin’s Lymphoma (NHL) Cell Activity in Association with Enhanced SPARC Expression but Independent of Its Ability to Strongly Inhibit NHL Cell VEGF Production In Vitro .

Ling-Hua Zhang, PhD, Peter Schafer, PhD, George Muller, PhD, David Stirling, PhD, J. Blake Bartlett, PhD
Journal: Blood
Blood (2007) 110 (11): 3473.
https://doi.org/10.1182/blood.V110.11.3473.3473
Published: 2007
Journal Articles

Lenalidomide Strongly Enhances Natural Killer (NK) Cell Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) of Rituximab Treated Non-Hodkin’s Lymphoma Cell Lines In Vitro .

Lei Wu, MD, Peter Schafer, PhD, George Muller, PhD, David Stirling, PhD, J. Blake Bartlett, PhD
Journal: Blood
Blood (2006) 108 (11): 3714.
https://doi.org/10.1182/blood.V108.11.3714.3714
Published: 2006
Journal Articles

New Approaches to the Regulation of Erythropoiesis and Hematoglobin Synthesis in β-Hemoglobinopathies: Studies with the Immunomodulatory Drug CC-4047.

Laure A. Moutouh de Parseval, MD, Dominique Verhelle, Ph.D., Emilia Glezer, B.S., Helen Brady, Ph.D., Laura G. Corral, M.S., Christopher L. Morris, M.D., Ph.D., George Muller, Ph.D., Kyle Chan, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 689.
https://doi.org/10.1182/blood.V108.11.689.689
Published: 2006
Journal Articles

Comparison of Anti-Angiogenic Activities of Thalidomide and Lenalidomide In Vitro.

Ling-Hua Zhang, PhD, Ling Lu, MS, Lei Wu, MS, Keith Dredge, PhD, J. Blake Bartlett, PhD, Peter Schafer, PhD, George Muller, PhD, Angus Dalgleish, PhD, David Stirling, PhD
Journal: Blood
Blood (2005) 106 (11): 3959.
https://doi.org/10.1182/blood.V106.11.3959.3959
Published: 2005
Journal Articles

Novel Immunomodulatory Drugs (IMiDs®): A Potential, New Therapy for β-Hemoglobinopathies.

Laure Moutouh de Parseval, MD., Helen Brady, PhD., Emila Glezer, MS., Normand Richard, MS., George Muller, PhD., Christopher L. Morris, MD., PhD., Dave Stirling, PhD., Kyle Chan, PhD.
Journal: Blood
Blood (2004) 104 (11): 3740.
https://doi.org/10.1182/blood.V104.11.3740.3740
Published: 2004
Journal Articles

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy

Teru Hideshima, Dharminder Chauhan, Yoshihito Shima, Noopur Raje, Faith E. Davies, Yu-Tzu Tai, Steven P. Treon, Boris Lin, Robert L. Schlossman, Paul Richardson, George Muller, David I. Stirling, Kenneth C. Anderson
Journal: Blood
Blood (2000) 96 (9): 2943–2950.
https://doi.org/10.1182/blood.V96.9.2943
Published: 2000